{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 18,
  "pageCount": 41,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a numbered list format to present key milestones and competitive advantages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/18",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.06,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Note: Photo credit: James Gathany. 1 Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial 2 Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates 3 Valneva reports positive End-of-Phase 2 Chikungunya meeting with the U.S. FDA and sets stage for Phase 3 Study; 4 https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority-review-voucher-program. 5 Valneva awarded FDA Fast Track Designation for Chikungunya vaccine candidate. 6 Valneva's Chikungunya vaccine candidate awarded EMA prime designation. 7 CHIKV LR2006-OPY1 infectious clone was attenuated by deleting large part of gene coding nsP3 (alphavirus-replicase). 8 Valneva to partner with Instituto Butantan on single-shot Chikungunya vaccine for low- and middle-Income countries.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e75a3067-07b5-41a6-85dd-30587c115479",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.18,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "image",
      "text": "Mosquito image",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c96a4d40-92d9-47e4-a388-d18a30e6c391",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.15,
        "y": 0.22
      },
      "kind": "list",
      "text": "1. Phase 3 trial VLA1553-301 fully enrolled; Use of surrogate marker for Ph3 endpoint confirmed by FDA; Accelerated Approval Pathway confirmed\n2. Potentially eligible for Priority Review Voucher; FDA Fast Track and EMA PRIME designation granted\n3. Single shot, live attenuated prophylactic vaccine targeting chikungunya virus neutralization\n4. Up to $23.4 million awarded to Valneva for R&D by CEPI; Partnership with Instituto Butantan for LMICs\n5. Excellent fit with existing commercial and manufacturing capabilities",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52863c90-1b17-43f4-9060-7a9016a3a85f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "VLA1553 – Only Chikungunya Vaccine Candidate in Phase 3 Today",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63281d9f-764b-4a33-9a45-a2a1d8c7f02a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}